Agranulocytosis due to deferiprone: a case report with cytomorphological and functional bone marrow examination.
作者信息
Masera Nicoletta, Tavecchia Luisa, Longoni Daniela Valentina, Maglia Oscar, Biondi Andrea, Masera Giuseppe
机构信息
Paediatric Clinic, University of Milano-Bicocca, San Gerardo Hospital, Monza, Italy.
出版信息
Blood Transfus. 2011 Oct;9(4):462-5. doi: 10.2450/2011.0098-10. Epub 2011 Jul 18.
Abstract
摘要
相似文献
1
Agranulocytosis due to deferiprone: a case report with cytomorphological and functional bone marrow examination.
Blood Transfus. 2011 Oct;9(4):462-5. doi: 10.2450/2011.0098-10. Epub 2011 Jul 18.
2
Necrotizing stomatitis: a possible periodontal manifestation of deferiprone-induced agranulocytosis.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009 Oct;108(4):e13-9. doi: 10.1016/j.tripleo.2009.06.021.
3
Agranulocytosis and thrombocytopenia in patient with Blackfan-Diamond anaemia during oral chelator trial.
Lancet. 1989 Aug 19;2(8660):457. doi: 10.1016/s0140-6736(89)90641-7.
4
Agranulocytosis and thrombocytopenia, Blackfan-Diamond anaemia, and oral chelation.
Lancet. 1990 Apr 21;335(8695):970. doi: 10.1016/0140-6736(90)91031-5.
5
Deferiprone-associated myelotoxicity.
Eur J Haematol. 1994 Nov;53(5):298-301. doi: 10.1111/j.1600-0609.1994.tb01323.x.
6
Agranulocytosis with deferiprone treatment of superficial siderosis.
BMJ Case Rep. 2013 Aug 7;2013:bcr2013010099. doi: 10.1136/bcr-2013-010099.
7
Deferiprone in iron overload.
N Engl J Med. 1995 Aug 31;333(9):598-9.
8
Development of oral iron chelator L1.
Lancet. 1993 Apr 24;341(8852):1088-9. doi: 10.1016/0140-6736(93)92444-x.
9
Idiosyncratic drug-induced agranulocytosis: the paradigm of deferiprone.
Hemoglobin. 2010 Jun;34(3):291-304. doi: 10.3109/03630269.2010.484791.
10
Safety Profile of Oral Iron Chelator Deferiprone in Chinese Children with Transfusion-Dependent Thalassaemia.
Curr Drug Saf. 2016;11(2):137-44. doi: 10.2174/1574886310666150930113957.
引用本文的文献
1
Iron Overload, Clonal Hematopoiesis, and Cancer Risk in Aging and Transfusion-Dependent Populations: A Literature Review.
Cureus. 2025 Jun 13;17(6):e85936. doi: 10.7759/cureus.85936. eCollection 2025 Jun.
2
Rates of severe neutropenia and infection risk in patients treated with deferiprone: 28 years of data.
Blood Adv. 2024 Nov 12;8(21):5641-5649. doi: 10.1182/bloodadvances.2023012316.
3
Deferiprone-induced agranulocytosis: 20 years of clinical observations.
Am J Hematol. 2016 Oct;91(10):1026-31. doi: 10.1002/ajh.24479. Epub 2016 Aug 4.
4
Agranulocytosis with deferiprone treatment of superficial siderosis.
BMJ Case Rep. 2013 Aug 7;2013:bcr2013010099. doi: 10.1136/bcr-2013-010099.
5
Safety and efficacy of iron chelation therapy with deferiprone in patients with transfusion-dependent thalassemia.
Ther Adv Hematol. 2012 Oct;3(5):299-307. doi: 10.1177/2040620712450252.
本文引用的文献
1
Idiosyncratic drug-induced agranulocytosis: the paradigm of deferiprone.
Hemoglobin. 2010 Jun;34(3):291-304. doi: 10.3109/03630269.2010.484791.
2
Improved survival in thalassemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiprone.
Haematologica. 2009 Dec;94(12):1777-8. doi: 10.3324/haematol.2009.009118. Epub 2009 Oct 8.
3
Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial.
Br J Haematol. 2009 Apr;145(2):245-54. doi: 10.1111/j.1365-2141.2009.07609.x. Epub 2009 Feb 19.
4
Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance.
J Cardiovasc Magn Reson. 2008 Sep 25;10(1):42. doi: 10.1186/1532-429X-10-42.
5
Febrile neutropenia and hemorrhagic stroke in a thalassemia major patient.
Hemoglobin. 2007;31(4):499-501. doi: 10.1080/03630260701641211.
6
Fatal agranulocytosis after deferiprone therapy in a child with Diamond-Blackfan anemia.
Blood. 2007 Jun 15;109(12):5157-9. doi: 10.1182/blood-2007-02-065805. Epub 2007 Mar 7.
7
Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
Ann Hematol. 2006 May;85(5):315-9. doi: 10.1007/s00277-005-0075-z. Epub 2006 Feb 1.
8
Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major.
Blood. 2006 May 1;107(9):3733-7. doi: 10.1182/blood-2005-07-2933. Epub 2005 Dec 22.
9
Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis.
Blood. 2006 May 1;107(9):3738-44. doi: 10.1182/blood-2005-07-2948. Epub 2005 Dec 13.
10
Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone.
Blood. 2003 Sep 1;102(5):1583-7. doi: 10.1182/blood-2002-10-3280. Epub 2003 May 22.
Zotero 插件